Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced a conference call scheduled for March 24, 2022, at 4:30 PM ET to discuss its fourth-quarter results for the period ending December 31, 2021. The call will focus on the performance and outlook for SBP-101, its lead product for treating metastatic pancreatic cancer, which has shown a median overall survival of 12 months and an objective response rate of 48% in clinical studies. Investors can participate via toll-free or international numbers, or through an online webcast.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces that an abstract for SBP-101, a proprietary polyamine analogue, will be presented at the American Association for Cancer Research (AACR) meeting from April 8-13, 2022. This research highlights a collaboration with Johns Hopkins University. SBP-101 aims to inhibit polyamine metabolism, showing promising results in clinical studies for metastatic pancreatic cancer, including a median overall survival of 12 months and an objective response rate of 48%. The safety profile indicates no exacerbation of common chemotherapy-related side effects.
Panbela Therapeutics (Nasdaq: PBLA) announced an agreement to acquire Cancer Prevention Pharmaceuticals to diversify its pipeline, targeting a $5 billion market for cancer therapies. The combined pipeline spans pre-clinical to registration studies, expected to generate significant catalysts. A fully funded registration trial for the lead asset will initiate by year-end. Post-merger, Panbela stockholders will hold approximately 59% of the company, while CPP stakeholders will own 41%. The deal aims to maximize shareholder value through operational synergies and enhanced patient treatment capabilities.
Panbela Therapeutics (Nasdaq: PBLA) has announced the launch of its global Phase 2 clinical trial, named the ASPIRE trial, for SBP-101 in combination with Gemcitabine and Nab-Paclitaxel to treat metastatic pancreatic ductal adenocarcinoma. The trial has begun at Summit Cancer Centers with plans to activate around 60 additional sites in 2022. The study is a randomized, double-blind, placebo-controlled trial focused on overall survival, with a completion target of patient enrollment within 12 months. SBP-101 has shown potential in previous studies without exacerbating common chemotherapy-related adverse effects.
Panbela Therapeutics (Nasdaq: PBLA) reported interim results from its Phase 1b study of SBP-101 in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma. The interim data revealed a median overall survival of 12.0 months and an objective response rate of 48%, both exceeding historical rates. Despite dose interruptions affecting results, cohort 2 showed an impressive 71% response rate. The safety profile indicated manageable Grade ≥3 adverse events. Panbela plans to advance to a Phase 2 randomized trial and explore additional indications.
Panbela Therapeutics (Nasdaq: PBLA) announced promising preclinical results for SBP-101 in ovarian cancer cell lines, highlighting its potential in a field of significant unmet medical need. The company aims to initiate a development program for SBP-101 in ovarian cancer in H1 2022 and will conduct a virtual R&D day to provide further insights. With ovarian cancer being a major cause of cancer deaths among women, the focus on SBP-101 underscores the importance of addressing this critical health issue.
Panbela Therapeutics (Nasdaq: PBLA) announced the acceptance of an abstract for a poster presentation of SBP-101 at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The presentation will focus on the efficacy of SBP-101, a polyamine metabolic inhibitor, in combination with gemcitabine and nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The safety profile shows no exacerbation of common chemotherapy-related adverse events. Further evaluation in a randomized clinical trial is planned.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) reported positive clinical progress and financial results for Q3 2021. The company highlighted that 16 patients are in survival follow-up, with two exceeding 28 months. A patent notification was issued for a new production method for SBP-101, reducing synthesis steps significantly. Financially, the company recorded a net loss of $2.1 million, or $0.16 per share, and reported cash and equivalents of $14.1 million. Management aims to initiate randomized trials and expand indications by year-end.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on November 10, 2021, at 4:30 PM ET to discuss its third-quarter results for the period ending September 30, 2021. Participants can join via a toll-free number or online. The company is developing SBP-101, a treatment targeting metastatic pancreatic cancer, with promising clinical signals of efficacy. Safety data from trials indicate that SBP-101 does not exacerbate chemotherapy-related adverse effects, which supports further clinical evaluation.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in two upcoming investor conferences:
- H.C. Wainwright 23rd Annual Global Investment Conference: September 13-15, 2021. Presentation available on-demand from September 13.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23, 2021, with a presentation on September 21 at 9:55am ET.
Management will host 1x1 investor meetings at both events. Panbela is focused on developing SBP-101, a treatment for pancreatic cancer.